Collegium Pharmaceutical Inc (COLL) Position Raised by Geode Capital Management LLC

Geode Capital Management LLC increased its position in shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) by 10.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 317,449 shares of the specialty pharmaceutical company’s stock after purchasing an additional 31,301 shares during the period. Geode Capital Management LLC owned 0.95% of Collegium Pharmaceutical worth $5,450,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in Collegium Pharmaceutical by 8.7% during the fourth quarter. BlackRock Inc. now owns 2,619,718 shares of the specialty pharmaceutical company’s stock worth $44,980,000 after purchasing an additional 210,145 shares during the last quarter. Vanguard Group Inc. increased its position in Collegium Pharmaceutical by 9.0% during the third quarter. Vanguard Group Inc. now owns 1,375,709 shares of the specialty pharmaceutical company’s stock worth $20,278,000 after purchasing an additional 113,038 shares during the last quarter. Vanguard Group Inc increased its position in Collegium Pharmaceutical by 9.0% during the third quarter. Vanguard Group Inc now owns 1,375,709 shares of the specialty pharmaceutical company’s stock worth $20,278,000 after purchasing an additional 113,038 shares during the last quarter. Morgan Stanley increased its position in Collegium Pharmaceutical by 20.1% during the third quarter. Morgan Stanley now owns 1,056,133 shares of the specialty pharmaceutical company’s stock worth $15,566,000 after purchasing an additional 176,577 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in Collegium Pharmaceutical by 2.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 663,498 shares of the specialty pharmaceutical company’s stock worth $11,392,000 after purchasing an additional 13,874 shares during the last quarter.

In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $17.17, for a total transaction of $429,250.00. Following the completion of the sale, the director now directly owns 227,362 shares in the company, valued at $3,903,805.54. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last quarter, insiders have sold 75,000 shares of company stock valued at $1,176,750. Company insiders own 8.08% of the company’s stock.

Several research firms recently issued reports on COLL. Zacks Investment Research cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Thursday, April 4th. BidaskClub cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday, March 26th. Finally, Cantor Fitzgerald set a $35.00 price objective on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Friday, April 12th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Collegium Pharmaceutical currently has a consensus rating of “Buy” and a consensus target price of $28.67.

Shares of COLL opened at $13.52 on Friday. Collegium Pharmaceutical Inc has a 1-year low of $13.10 and a 1-year high of $28.91. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.26 and a quick ratio of 1.21.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.65. Collegium Pharmaceutical had a negative net margin of 13.95% and a negative return on equity of 41.12%. The business had revenue of $73.40 million during the quarter, compared to analysts’ expectations of $72.71 million. During the same period last year, the business earned ($0.54) earnings per share. The business’s revenue for the quarter was up 579.6% on a year-over-year basis. Equities research analysts forecast that Collegium Pharmaceutical Inc will post -0.31 EPS for the current year.

WARNING: “Collegium Pharmaceutical Inc (COLL) Position Raised by Geode Capital Management LLC” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2019/04/21/collegium-pharmaceutical-inc-coll-position-raised-by-geode-capital-management-llc.html.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Featured Story: What is Net Asset Value (NAV)?

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical Inc (NASDAQ:COLL).

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.